| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Heyman Richard A. serves as a Director at ORIC and has filed Form 4s across 3 companies. Across recent SEC filings that breaks down to 0 buys and 58 sells. Those positions are worth an estimated $4.3M at current prices.
Historically, Heyman Richard A.'s trades have earned a strong insider score of 74/100 across 37 rated trades. Over a 12-month horizon, 77.1% of those trades were profitable, with an average 12-month return of +35.1%.
The biggest single holding is ORIC (~$2.8M) as Director. The recent filings there lean toward selling, a net 31,028 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 24, 2026 | ORIC Oric Pharmaceuticals, Inc. | Director | Sale+OE | 13,100 | $12.02 | $157,462.00 | -5.1% | - | - | |
| Jan 16, 2026 | ORIC Oric Pharmaceuticals, Inc. | Director | Sell | 6,700 | $12.00 | $80,430.82 | -2.6% | - | - | |
| Jan 9, 2026 | ELVN Enliven Therapeutics, Inc. | Director | Sell | 13,920 | $25.02 | $348,280.95 | -14.8% | +75.3% | - | |
| Oct 18, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell | 1,570 | $30.00 | $47,104.03 | -1.0% | -24.2% | -26.2% | |
| Oct 15, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell | 1,270 | $27.67 | $35,143.31 | -1.0% | -20.7% | -21.9% | |
| Oct 4, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell | 2,825 | $27.51 | $77,703.60 | -2.2% | -13.2% | -28.8% | |
| Oct 1, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell | 518 | $27.54 | $14,264.32 | -0.4% | -13.9% | -23.8% | |
| Sep 16, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell | 1,270 | $22.41 | $28,458.16 | -1.0% | +5.3% | -17.6% | |
| Aug 15, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell | 1,270 | $23.25 | $29,526.20 | -0.5% | +8.5% | -14.9% | |
| Jul 31, 2024 | ELVN Enliven Therapeutics, Inc. | Director | Sell | 2,351 | $27.50 | $64,662.54 | -1.5% | +8.1% | -28.7% |